CR20210318A - Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf - Google Patents
Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegfInfo
- Publication number
- CR20210318A CR20210318A CR20210318A CR20210318A CR20210318A CR 20210318 A CR20210318 A CR 20210318A CR 20210318 A CR20210318 A CR 20210318A CR 20210318 A CR20210318 A CR 20210318A CR 20210318 A CR20210318 A CR 20210318A
- Authority
- CR
- Costa Rica
- Prior art keywords
- high concentration
- antibody
- protein solution
- formulation containing
- vegf antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indicating Or Recording The Presence, Absence, Or Direction Of Movement (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-VEGF formulados como alta concentración, composiciones farmacéuticas acuosas, adecuadas para una inyección, con preferencia una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para el suministro de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpos y sin un alto nivel de material particulado sub-visible. Una composición acuosa de la divulgación comprende un anticuerpo que tiene una concentración de al menos 50 mg/ml. Una composición farmacéutica acuosa de la divulgación incluye un azúcar, un agente tamponador, y un surfactante
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781003P | 2018-12-18 | 2018-12-18 | |
| PCT/IB2019/060859 WO2020128792A1 (en) | 2018-12-18 | 2019-12-16 | Protein solution formulation containing high concentration of an anti-vegf antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210318A true CR20210318A (es) | 2021-07-14 |
Family
ID=69165422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210318A CR20210318A (es) | 2018-12-18 | 2019-12-16 | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11945859B2 (es) |
| EP (1) | EP3897714A1 (es) |
| JP (2) | JP7089121B2 (es) |
| KR (1) | KR20210106476A (es) |
| CN (1) | CN113194993A (es) |
| AR (1) | AR117707A1 (es) |
| AU (1) | AU2019407063B2 (es) |
| BR (1) | BR112021011290A2 (es) |
| CA (1) | CA3119241A1 (es) |
| CL (1) | CL2021001587A1 (es) |
| CO (1) | CO2021007830A2 (es) |
| CR (1) | CR20210318A (es) |
| EC (1) | ECSP21043639A (es) |
| IL (1) | IL283456A (es) |
| JO (1) | JOP20210152A1 (es) |
| MX (1) | MX2021007393A (es) |
| MY (1) | MY206282A (es) |
| NZ (1) | NZ775956A (es) |
| PE (1) | PE20211602A1 (es) |
| PH (1) | PH12021551307A1 (es) |
| SG (1) | SG11202104653XA (es) |
| TW (1) | TWI857996B (es) |
| WO (1) | WO2020128792A1 (es) |
| ZA (1) | ZA202102986B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104004094B (zh) | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| KR20250051157A (ko) | 2019-06-05 | 2025-04-16 | 리제너론 파아마슈티컬스, 인크. | 정밀 투여량 전달을 위한 디바이스 및 방법 |
| CN117820474A (zh) * | 2023-04-25 | 2024-04-05 | 南京贝思奥生物科技有限公司 | 改善眼部血管新生相关疾病的药物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| HUE032894T2 (hu) | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | VEGF-gátló, stabilis és oldható antitestek |
| CN104004094B (zh) | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| JP2014519520A (ja) | 2011-06-16 | 2014-08-14 | ロンザ・リミテッド | ペプチドの抽出方法および液相ペプチド合成におけるその使用 |
| BR112013030472A2 (pt) | 2011-06-30 | 2019-09-24 | Genentech Inc | formulação farmacêutica, artigo de fabricação e método |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| AU2019235577B2 (en) | 2018-03-16 | 2021-09-30 | Novartis Ag | Methods for treating ocular diseases |
-
2019
- 2019-12-16 MX MX2021007393A patent/MX2021007393A/es unknown
- 2019-12-16 KR KR1020217021741A patent/KR20210106476A/ko active Pending
- 2019-12-16 NZ NZ775956A patent/NZ775956A/en unknown
- 2019-12-16 PH PH1/2021/551307A patent/PH12021551307A1/en unknown
- 2019-12-16 EP EP19836538.9A patent/EP3897714A1/en active Pending
- 2019-12-16 BR BR112021011290A patent/BR112021011290A2/pt unknown
- 2019-12-16 TW TW108146070A patent/TWI857996B/zh active
- 2019-12-16 JO JOP/2021/0152A patent/JOP20210152A1/ar unknown
- 2019-12-16 JP JP2021534608A patent/JP7089121B2/ja active Active
- 2019-12-16 AR ARP190103687A patent/AR117707A1/es unknown
- 2019-12-16 WO PCT/IB2019/060859 patent/WO2020128792A1/en not_active Ceased
- 2019-12-16 CR CR20210318A patent/CR20210318A/es unknown
- 2019-12-16 MY MYPI2021002599A patent/MY206282A/en unknown
- 2019-12-16 PE PE2021000916A patent/PE20211602A1/es unknown
- 2019-12-16 CA CA3119241A patent/CA3119241A1/en active Pending
- 2019-12-16 US US16/715,580 patent/US11945859B2/en active Active
- 2019-12-16 SG SG11202104653XA patent/SG11202104653XA/en unknown
- 2019-12-16 AU AU2019407063A patent/AU2019407063B2/en active Active
- 2019-12-16 CN CN201980081759.8A patent/CN113194993A/zh active Pending
-
2021
- 2021-05-04 ZA ZA2021/02986A patent/ZA202102986B/en unknown
- 2021-05-25 IL IL283456A patent/IL283456A/en unknown
- 2021-06-15 CO CONC2021/0007830A patent/CO2021007830A2/es unknown
- 2021-06-16 CL CL2021001587A patent/CL2021001587A1/es unknown
- 2021-06-16 EC ECSENADI202143639A patent/ECSP21043639A/es unknown
-
2022
- 2022-04-20 JP JP2022069588A patent/JP2022105056A/ja active Pending
-
2024
- 2024-02-16 US US18/444,288 patent/US20240182554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551307A1 (en) | 2022-05-16 |
| KR20210106476A (ko) | 2021-08-30 |
| WO2020128792A1 (en) | 2020-06-25 |
| JP2022105056A (ja) | 2022-07-12 |
| JP2022513253A (ja) | 2022-02-07 |
| MX2021007393A (es) | 2021-09-23 |
| CL2021001587A1 (es) | 2022-02-11 |
| AU2019407063B2 (en) | 2024-07-04 |
| BR112021011290A2 (pt) | 2021-11-03 |
| AU2019407063A1 (en) | 2021-05-27 |
| ECSP21043639A (es) | 2021-07-30 |
| CA3119241A1 (en) | 2020-06-25 |
| CO2021007830A2 (es) | 2021-06-21 |
| JOP20210152A1 (ar) | 2023-01-30 |
| CN113194993A (zh) | 2021-07-30 |
| US20240182554A1 (en) | 2024-06-06 |
| US11945859B2 (en) | 2024-04-02 |
| EP3897714A1 (en) | 2021-10-27 |
| SG11202104653XA (en) | 2021-07-29 |
| US20200190179A1 (en) | 2020-06-18 |
| PE20211602A1 (es) | 2021-08-18 |
| TWI857996B (zh) | 2024-10-11 |
| JP7089121B2 (ja) | 2022-06-21 |
| IL283456A (en) | 2021-07-29 |
| AR117707A1 (es) | 2021-08-25 |
| NZ775956A (en) | 2024-12-20 |
| TW202031289A (zh) | 2020-09-01 |
| MY206282A (en) | 2024-12-06 |
| ZA202102986B (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| EA201492021A1 (ru) | Антительный состав | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| WO2012076670A3 (en) | Antibody formulation | |
| RU2011140498A (ru) | Препарат антител | |
| PE20050394A1 (es) | FORMULACIONES DE ANTICUERPO MONOCLONAL anti-lge ALTAMENTE CONCENTRADO | |
| PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| RU2019125947A (ru) | Новые стабильные композиции для fxia антител |